Comments on ICER’s Draft Evidence Report for Aducanumab for Alzheimer’s Disease
Alzheimer’s and dementia already afflict too many people, yet their prevalence is expected to more than double in the coming decades. Effective Alzheimer’s treatments will reduce the disease’s economic costs today and will significantly decrease the expected cost burdens of the disease in the future. Read Comments
ICER’s Evaluation of Alzheimer’s Treatment Undervalues Key Groups
The Institute for Clinical and Economic Review claims that the first disease-modifying treatment for Alzheimer’s disease isn’t worth its cost.
Who Will Control Access to New Alzheimer’s Treatments?
Very few of the more than 5 million Americans, or their caregivers, who live with Alzheimer’s have ever heard of the Institute for Clinical and Economic Review.
